Sesen Bio Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Sesen Bio's estimated annual revenue is currently $5.7M per year.
- Sesen Bio received $9.0M in venture funding in March 2018.
- Sesen Bio's estimated revenue per employee is $155,000
- Sesen Bio has 37 Employees.
- Sesen Bio grew their employee count by 32% last year.
- Sesen Bio currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$89.4M||577||N/A||N/A|
What Is Sesen Bio?
We are passionate in our commitment to improving and renewing people's lives. Sesen Bio is a late-stage company developing fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body's innate immune response system. The most advanced program in our pipeline is Vicinium, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium's potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors. The first assessment of this is in a clinical study combing Vicinium with AstraZeneca's durvalumab, in NMIBC. For more information, please visit www.sesenbio.com.keywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Dennis Kim||Chief Medical Officer|
|Sachin Pannuri||Sr Director, CMC||Email Available|
|Madhu Anant||VP Head, Regulatory Affairs||Email Available|
|Tom Cannell||President and CEO||Email Available|
|Chad Myskiw||Supply Chain Project Manager||Email Available|
|Arjune Premsukh||Director||Email Available|
|Jodi Luht||Director Of Quality||Email Available|
|Rachelle Dillon||Associate Director, Clinical Operations Support||Email Available|
|Erin Clark||Vice President, Corporate Strategy & Investor Relations||Email Available|
|Thomas Cannell||President/CEO||Email Available|
Sesen Bio News
Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer. Sesen Bio (Nasdaq: SESN), ...
The recent performance of Sesen Bio (NASDAQ:SESN) stock in the market spoke loud and clear to investors as SESN saw more than 2.19M ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein ...
Sesen Bio Funding
|2010-02-18||$35.0M||A||Flagship Ventures, Third Rock Ventures||Article|
|2012-05-09||$20.0M||Undisclosed||JAFCO Co Ltd||Article|
|2014-11-26||$20.0M||Undisclosed||Citigroup Global Markets Inc||Article|
|2017-11-03||$8.0M||Undisclosed||H.C. Wainwright & Co., LLC||Article|
Sesen Bio Executive Hires
|2011-01-07||Eric Furfine||Pres R/D||Article|
|2013-07-01||Karen L. Tubridy||Chief Development Officer||Article|
|2014-01-03||Gregory D. Perry||Chief Financial/Business Officer||Article|
|2014-05-06||Gary Sternberg||EVP Corporate/Business Development||Article|
|2017-05-17||David Brooks||SVP Clinical Dev||Article|
|2017-05-18||David Brooks||Senior Vice President, Clinical Development||Article|
|2017-10-16||Richard Fitzgerald||Interim Chief Financial Officer||Article|
|2017-12-14||Gregory Adams||Chief Scientific Officer||Article|